Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.
D Ross CamidgeJair BarHidehito HorinouchiJonathan Wade GoldmanFedor V MoiseyenkoElena FilippovaIrfan CicinTudor CiuleanuNathalie DaaboulChunling LiuPenelope BradburyMor MoskovitzNuran KatgiPascale TomasiniAlona Zer KuchNicolas GirardKristof CuppensJi-Youn HanShang-Yin WuShobhit BaijalAaron S MansfieldAllen Chung-Cheng HuangKazumi NishinoSe-Hoon LeeDavid PlanchardChristina BaikMartha LiPeter AnsellSummer XiaEllen BolotinJim LoomanChristine RatajczakShun LuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable.